Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adelina Sementa

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
The New England Journal of Medicine|June 14, 2008
Rituximab in relapsing-remitting multiple sclerosisRaffaele De Palma, Adelina Sementa
European Journal of Haematology|March 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 PatientsFortunato Morabito, Enrica Antonia Martino, Monica Galli, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
The New England Journal of Medicine|June 14, 2008
Rituximab in relapsing-remitting multiple sclerosisRaffaele De Palma, Adelina Sementa
European Journal of Haematology|March 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 PatientsFortunato Morabito, Enrica Antonia Martino, Monica Galli, et al.
Pageof 1